Steven DuBois

Steven DuBois, MD, MS is an Associate Professor of Pediatrics at Harvard Medical School and serves as the Director of Experimental Therapeutics at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center. His clinical practice focuses on pediatric oncology with specialization in treating children and young adults with solid cancers, particularly Ewing sarcoma and neuroblastoma.

• Harvard Medical School - Faculty Position
• Dana-Farber/Boston Children's Cancer and Blood Disorders Center - Director of Experimental Therapeutics
• Children's Oncology Group - Active Researcher and Committee Member

Dr. DuBois received his medical degree from UCSF School of Medicine in 2000. He completed his pediatric internship and residency at the University of California, San Francisco, School of Medicine in 2001 and 2003, respectively. His fellowship in Pediatric Hematology-Oncology was completed at Boston Children's Hospital/Dana-Farber Cancer Institute in 2007. He is board certified by the American Board of Pediatrics in Hematology-Oncology.

Dr. DuBois's research primarily focuses on developing new targeted agents for childhood cancer treatment. His work spans several key areas including Ewing sarcoma therapeutic development, neuroblastoma treatment strategies, molecular radiotherapy approaches, and precision medicine applications in pediatric oncology. He has made significant contributions to understanding tumor biology, developing novel therapeutic approaches, and addressing health disparities in pediatric cancer outcomes. His research integrates clinical trials with molecular profiling to advance personalized treatment approaches for children with solid tumors.

Analysis of Dr. DuBois's recent publications (2024-2025) reveals a strong emphasis on precision oncology approaches for pediatric solid tumors. His work spans multiple domains including molecular characterization of tumors, development of targeted therapies, optimization of radiotherapy approaches, and addressing health disparities in cancer outcomes. A significant portion of his research involves Children's Oncology Group studies, demonstrating his leadership in collaborative multi-institutional research. His publications highlight expertise in both Ewing sarcoma and neuroblastoma, with increasing focus on molecularly targeted therapies and precision medicine approaches.

Dr. DuBois leads a research team dedicated to developing new targeted agents for childhood cancer treatment. His work involves extensive collaboration with the Children's Oncology Group and participation in numerous clinical trials focused on novel therapeutic approaches for pediatric solid tumors. His leadership as Director of Experimental Therapeutics at Dana-Farber/Boston Children's positions him at the forefront of translating laboratory discoveries into clinical applications for children with cancer.